Rewind: Roche returns to phase 2 after seeing post hoc signal in failed pivotal...

[cafead]

via Ionis Pharmaceuticals-partnered tominersen looked to be down and out when Roche revealed the extent of its phase 3 failure in patients with Huntington's disease last year. But an encouraging signal in the wreckage of the clinical trial has offered a reprieve—and persuaded Roche to wind back to phase 2 to see whether the sign of efficacy holds up to rigorous study.

article source